Tirofiban Lacks Efficacy in Acute Stroke Patients Receiving Thrombectomy

A new study found no disability benefit, plus an increase in symptomatic intracranial hemorrhage.

A substantial proportion of patients are still disabled after endovascular thrombectomy (EVT) for acute ischemic stroke with large vessel occlusion, and it is unclear whether adjunctive antithrombotic medications could be useful in improving outcomes. In a 3-year study, investigators in China randomized 948 patients (mean age, 67; 41% men) to standard EVT within 24 hours of stroke onset, plus either the glycoprotein IIb/IIIa inhibitor tirofiban or placebo, administered as a bolus and then infused over 24 hours. The primary outcome was change in the modified Rankin Scale (mRS) at 90 days, and the main safety outcome was the incidence of symptomatic intracranial hemorrhage (sICH) within 48 hours.

Strokes were fairly severe (median NIH Stroke S…

Reviewing Author

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Tirofiban Lacks Efficacy in Acute Stroke Patients Receiving Thrombectomy

Topics

Reviewing Author